Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients.

Asian Pacific journal of cancer prevention : APJCP - 1 Feb 2021

Annuar Aziati Azwari, Ankathil Ravindran, Mohd Yunus Nazihah, Husin Azlan, Ab Rajab Nur Shafawati, Abdul Aziz Ahmad Aizat, Ibrahim Mohd Ismail, Sulong Sarina

Abstract excerpt

BACKGROUND: The FAS mediated apoptosis pathway involving the FAS and FASL genes plays a crucial role in the regulation of apoptotic cell death and imatinib mesylate (IM) mechanism of action. Promoter polymorphisms FAS-670 A>G and FAS-844 T>C which alter the transcriptional activity of these genes may grant a risk to develop cancer and revamp the drug activities towards the cancer cell. We investigated the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Fas Ligand Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Logistic Models

Share to Malaysia

Share to Promoter Regions, Genetic

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 33639675
DOI: 10.31557/APJCP.2021.22.2.565
PMCID: PMC8190357

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients.PMID 33639675Read ↗

Association of promoter polymorphisms of Fas -FasL genes with development of Chronic Myeloid Leukemia.Semantic proximity Read ↗

Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia.Semantic proximity Read ↗

Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia.Semantic proximity Read ↗

Significant association between FasL gene -844T/C polymorphism and risk to hepatocellular carcinoma in Egyptian patients.Semantic proximity Read ↗

Fas and FasL polymorphisms are not associated with acute myeloid leukemia risk in Koreans.Semantic proximity Read ↗

The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia.Semantic proximity Read ↗

Expression of DR4, DR5, FAS, Caspase-8 and, DDIAS Genes in AML PatientsSemantic proximity Read ↗

The rs61764370 Functional Variant in the KRAS Oncogene is Associated with Chronic Myeloid Leukemia Risk in Women.Semantic proximity Read ↗

Single-Nucleotide Polymorphisms of FAS and FASL Genes and Risk of Idiopathic Aplastic Anemia.Semantic proximity Read ↗

Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases.Semantic proximity Read ↗

Methylenetetrahydrofolate reductase gene polymorphisms contribute to acute myeloid leukemia and chronic myeloid leukemia susceptibilities: evidence from meta-analyses.Semantic proximity Read ↗

Association of GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms with clinical response to imatinib mesylate treatment among Malaysian chronic myeloid leukaemia patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.